European RAT Clinical Trial Halted to Refocus Initiatives
Filed with ASX · · 2 pages · English
AnteoTech Ltd (ASX: ADO) (“AnteoTech” or “the Company”) advises that following the first stage of an operational review, a decision has been made to halt the EuGeni SARS-CoV-2 Ag RDT1 European clinical trial and divert resources and funding from the trial to enable the acceleration of the COVID- 19 Flu A / Flu B Multiplex and/or other Point of Care (POC) tests currently being considered by AnteoTe
Earlier from AnteoTech
- FY22 Results Announcement
- Appendix 4E Preliminary Final Report
- CEO Appointment
- AnteoX Performance Validated by Two Global Battery Companies
- Application for quotation of securities - ADO
Later from AnteoTech
- Managing Director AGM Presentation
- AnteoTech receives $3.2m R&D Tax Incentive
- Response to ASX Query
- Appendix 4D and Interim Financial Report
- AnteoTech signs MOU with Trinseo
Follow AnteoTech into a list and get an email when it puts out news.
Follow AnteoTech